You are here

Coronavirus (COVID-19): Information on medicines and medical devices

The TGA is publishing the latest information about medicines and medical devices as it relates to COVID-19 on this page.

Please read the information below before contacting the TGA to see if your question is already answered.

2 December 2021

COVID-19 treatments undergoing evaluation for provisional registration by the TGA

2 December 2021

COVID-19 treatments that have received a provisional determination from the TGA

1 December 2021

COVID-19 treatments that have been provisionally approved for use in Australia

1 December 2021
On 1 December 2021, the TGA granted provisional approval to Roche Products Pty Ltd for the use of tocilizumab (ACTEMRA) for the treatment of COVID-19.
30 November 2021

Find out which vaccines we recognise for the purpose of travel to Australia.

30 November 2021
The TGA has issued three infringement notices totalling $7,992 to an individual for allegedly advertising ivermectin and zinc lozenges to treat COVID-19 in breach of the Therapeutic Goods Act 1989.
29 November 2021

Find information about advertising COVID-19 rapid tests.

26 November 2021
The TGA is undertaking a post-market review of face masks included in the ARTG. This page lists all face masks that have been cancelled from the ARTG during the review.
25 November 2021

COVID-19 vaccines undergoing evaluation for provisional registration by the TGA

25 November 2021
On 15 October 2021 the TGA granted provisional approval to Roche Products Pty Ltd for its COVID-19 treatment - casirivimab + imdevimab (RONAPREVE) - making it the third COVID-19 treatment to receive regulatory approval in Australia.

Pages

Further information

Contact TGA Info

Tel: 1800 020 653
Email: info@tga.gov.au

Note: we are currently experiencing a high volume of calls and emails. Please bear with us as we try to respond to queries as quickly as possible.

Department of Health

Coronavirus (COVID-19) health alert — for information and advice not specific to therapeutic goods.

Follow us